Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: sitaxsentan sodium Clear all

Conditions: Pulmonary Hypertension
Interventions: sitaxsentan sodium; Drug
Lead sponsor: ICOS-Texas Biotechnology; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 21 more

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
Interventions: Sitaxsentan, Bosentan, Ambrisentan; Drug
Lead sponsor: West Penn Allegheny Health System; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Sitaxsentan, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Fountain Valley, California • Mather, California • Sacramento, California + 28 more

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Sitaxsentan, Sitaxsentan and Sildenafil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 12
States / cities: Fountain Valley, California • Gainesville, Florida • Weston, Florida + 9 more

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Sitaxsentan, Sitaxsentan and Sildenafil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Fountain Valley, California

Conditions: Healthy
Interventions: Sitaxentan sodium/Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Diastolic Heart Failure
Interventions: Sitexsentin sodium, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 50
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 39 more

Conditions: Pulmonary Hypertension
Interventions: sitaxsentan sodium; Drug
Lead sponsor: Encysive Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: Sitaxsentan; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more

Conditions: Heart Disease
Interventions: 1mg/kg sitaxsentan sodium, 2mg/kg sitaxsentan sodium, Vehicle; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension

Pharmacogenomics in Pulmonary Arterial Hypertension

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil

Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety

Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects

A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure

Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

Proteolytic Enzyme Induction Within the Human Myocardial Interstitium